Glaser Weil Represents NAYA Biosciences in $9.5 Million Public Offering

Glaser Weil is proud to announce its representation of NAYA Biosciences, Inc. (Nasdaq: NAYA), a life science portfolio company committed to breakthrough treatments in oncology, autoimmune diseases and women’s health, in its $9.5 million public offering.

The offering consisted of 13,615,171 units at a public offering price of $0.70 per unit. Each unit includes one share of common stock (or pre-funded warrant in lieu thereof) and one warrant to purchase one share of common stock at an exercise price of $0.70. The warrants are immediately exercisable and will expire five years from the issuance date.

The gross proceeds from the offering will support NAYA's strategic initiatives, including funding an installment for the purchase of the Wisconsin Fertility Institute, redeeming preferred stock, addressing outstanding debt obligations, and advancing clinical trials, product development and corporate growth initiatives.

The Glaser Weil corporate team was led by Partner and Corporate Department Co-chair Marc Indeglia, with assistance from associate Josephine Wu.

This offering follows Glaser Weil’s recent representation of INVO Bioscience in its merger with NAYA Biosciences. NAYA’s public offering marks a significant step in its mission to expand access to innovative treatments and reflects the company’s ongoing commitment to enhancing patient care.

For more information, read the press release.